Biotechnology

Happiness Development Group Limited Received Nasdaq Notification Letter Regarding Bid Price Deficiency

NANPING, China, Nov. 16, 2021 /PRNewswire/ -- Happiness Development Group Limited ("HAPP" or the "Company"),(NASDAQ: HAPP) announced today that the Company received a notification letter from the Nasdaq Listing Qualifications Staff of The NASDAQ Stock Market LLC ("Nasdaq") onNovember 11, 2021, no...

2021-11-16 21:00 1245

Kazia Therapeutics Appoints John Friend, MD, as Chief Medical Officer

SYDNEY, Nov. 15, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce the appointment ofJohn Friend, MD, as Chief Medical Officer. In this role, Dr. Friend will be responsible for overseeing the developme...

2021-11-16 00:00 1733

CARsgen Announces CAR T-cell Product Candidate CT041 Granted PRIME Eligibility by the EMA

SHANGHAI, Nov. 15, 2021 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, today announced that the European Medicines Agency (EMA) has granted Priority M...

2021-11-15 22:10 4265

Validation Study Showcases Success of LSBD's Rapid SARS-CoV-2 Antibody Test

SYDNEY, Nov. 15, 2021 /PRNewswire/ -- The iQ Group Global Ltd (iQG Ltd) (NSX:IQG) on behalf of Life Science Biosensor Diagnostics Pty Ltd (LSBD), has announced the successful completion of a clinical validation study showcasing the efficacy of its rapid SARS-Cov-2 Antibody test. The results of ...

2021-11-15 22:00 1297

InnoCare Announces the Clearance of Clinical Trial of Novel SHP2 Allosteric Inhibitor ICP-189 by U.S. FDA

BEIJING, Nov. 14, 2021 /PRNewswire/ -- InnoCare Pharma (HKEX: 09969), a commercial-stage biotech company, announced today the Investigational New Drug (IND) clearance of itsSHP2 (Src Homology 2 domain containing protein tyrosine phosphatase) allosteric inhibitor ICP-189 by the US Food and Drug A...

2021-11-15 08:30 1514

China Pharma Holdings, Inc. Reports Third Quarter 2021 Financial Results

HAIKOU, China, Nov. 12, 2021 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI)  ("China Pharma," the "Company" or "We"), an NYSE American-listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based inChina, today announced the financial results for the qu...

2021-11-13 05:30 4476

Tabernacle Health Group Launches Revolutionary Immunity Booster. Natural Health Supplement Avrocil (TM) Treats Cold and Flu Symptoms caused by Upper Respiratory Tract Infections

SINGAPORE, Nov. 11, 2021 /PRNewswire/ -- The pandemic sped up participation in virtual exercise classes acrossthe United States, as countless fitness enthusiasts switched to indoor workouts to avoid viruses, such as those that lead to accelerated upper respiratory tract infections, whose sympto...

2021-11-12 02:00 1602

Lunit Presents Studies at SITC 2021, Highlighting the Effectiveness of AI in Predicting Response to Immunotherapy in a Clinical Trial Setting

-  Lunit to present three abstracts about its AI biomarker platform Lunit SCOPE IO, also to be  demonstrated during the event in booth #423 -  One immunotherapy combination study adds significant evidence for the potential value of using Lunit SCOPE IO in clinical practice to predict patient res...

2021-11-11 23:00 1350

Happiness Biotech Group Limited Announces Name Change to Happiness Development Group Limited and Re-Designation of Its Ordinary Shares

NANPING, China, Nov. 11, 2021 /PRNewswire/ -- Happiness Biotech Group Limited (" Happiness" or the "Company"), (NASDAQ: HAPP), is pleased to announce that effective onNovember 12, 2021, the Company will change its name to "Happiness Development Group Limited" (the "Name Change"). In addition, the ...

2021-11-11 21:00 1235

Hummingbird Bioscience Announces Trials in Progress Poster Presentation at the Society for Immunotherapy of Cancer 2021 36th Annual Meeting

HOUSTON, Nov. 10, 2021 /PRNewswire/ -- Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets, today announced a Trials in Progress poster presentation outlining the Phase 1 clinical trial design for HMBD-002, a ...

2021-11-10 17:00 1368

I-Mab and ABL Bio Report Preclinical Data of 4-1BB-targeting Bispecific Antibodies at 2021 SITC

* Preclinical data of TJ-CD4B/ABL111 and TJ-L14B/ABL503 demonstrate targeted safety profile and enhanced anti-tumor activity * Both studies are undergoing phase 1 clinical trials in the United States SHANGHAI and GAITHERSBURG, Md. and SEONGNAM, South Korea, Nov. 9, 2021 /PRNewswire/ -- I-Mab ...

2021-11-09 21:05 1456

Alterity Therapeutics Announces Presentation of ATH434 at the American Autonomic Society Virtual Meeting 2021

MELBOURNE, Australia, Nov. 9, 2021 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative conditions, today announced a poster presentation and accompanying vi...

2021-11-09 20:30 1285

InnoRNA of China participates in the Hanmi Science Consortium …"To join forces to eliminate 'vaccine divide'"

SEOUL, South Korea, Nov. 9, 2021 /PRNewswire/ -- Global businesses and institutes are knocking on the door to the Hanmi Science Consortium having proprietary LNP technology. After Hanmi Science concluded a 'pandemic science alliance agreement' with theUniversity of Oxford, increasingly more entit...

2021-11-09 14:20 1323

InnoCare to Present Orelabrutinib Data at the Upcoming 63rd Annual Meeting of ASH

BEIJING, Nov. 9, 2021 /PRNewswire/ -- InnoCare Pharma (HKEX: 09969), a leading biotech company, announced today that the company will present latest data of its BTK inhibitor orelabrutinib at the 63rd American Society of Hematology (ASH) Annual Meeting onDecember 11-14, 2021, which will be hold o...

2021-11-09 13:06 1655

Standigm Established a Synthetic Research Center to Improve Efficiency of AI Drug Discovery

SEOUL, South Korea, Nov. 8, 2021 /PRNewswire/ -- Standigm Inc. ("Standigm"), the leading workflow artificial intelligence (AI) drug discovery company, announced today that the company had established a Synthetic Research Center in the headquarters of SK Chemicals Co., Ltd ("SK Chemicals", KRX 285...

2021-11-09 10:47 1852

BIORCHESTRA will present data on the therapeutic efficacy of their proprietary ASO against pathological miRNA, a key modulator of neuroinflammation and neurodegeneration, at the CTAD Meeting in Boston

BOSTON, Nov. 5, 2021 /PRNewswire/ -- South Korean bio-venture BIORCHESTRA Co. Ltd., is an RNA therapeutics firm focused on neurodegeneration.  BIORCHESTRA discovered a disease-associated microRNA that was found to be significantly up-regulated in samples from Alzheimer's disease patients. It then...

2021-11-08 22:59 2648

Ascentage Pharma Announces Clinical Trial Agreement to Evaluate the Combination of Lisaftoclax (APG-2575) and the CDK4/6 Inhibitor IBRANCE® (Palbociclib) in Metastatic ER+/HER2- Breast Cancer

SUZHOU, China, and ROCKVILLE, Md., Nov. 8, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced a clinical trial collaborati...

2021-11-08 21:47 2054

Farmmi Announces Latest Multi-Product Sales Win

LISHUI, China, Nov. 8, 2021 /PRNewswire/ -- Farmmi, Inc. ("Farmmi" or the "Company") (NASDAQ: FAMI), an agriculture products supplier inChina, today announced the Company's subsidiary Zhejiang Farmmi Biotechnology Co., Ltd., won a new multi-product order for its popular dried black fungus and who...

2021-11-08 21:00 1279

Everest Medicines Announces Up to HK$100 million Additional Share Repurchase Program

SHANGHAI, Nov. 7, 2021 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest" or the "Company"), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients inAsia, today announced that i...

2021-11-08 08:10 1699

PromarkerD significantly outperforms current standard of care tests in predicting future kidney function decline

* Study shows PromarkerD is significantly better than current standard of care tests eGFR and ACR for predicting future decline in kidney function in patients with type 2 diabetes * PromarkerD correctly identified 84% of patients with normal kidney function that went on to experience kidney f...

2021-11-05 20:37 1618
1 ... 76777879808182 ... 114